Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Patent tenofovir alafenamide gilead?Campath litigation germany?Sun pharma bortezomib?How does renal function impact tigecycline's liver safety?Norcuron generic name?
See the DrugPatentWatch profile for keytruda
Keytruda (pembrolizumab) received its initial FDA approval for the treatment of unresectable or metastatic melanoma.
The initial FDA approval for Keytruda was granted in 2014.
At first approval, Keytruda was indicated for patients with unresectable or metastatic melanoma (a cancer type where the drug later expanded into many additional indications).
[1] https://www.drugpatentwatch.com/
Other Questions About Keytruda :